Alnylam Pharmaceuticals (ALNY) News Today $248.85 -2.15 (-0.86%) As of 02:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Ieq Capital LLC Acquires 34,613 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Ieq Capital LLC raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 825.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 38,806 shares of theFebruary 21 at 4:44 AM | marketbeat.comVontobel Holding Ltd. Has $424,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Vontobel Holding Ltd. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 75.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,804 shares of the biopharmaceutical compFebruary 21 at 3:12 AM | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $385.00 at Canaccord Genuity GroupFebruary 20 at 1:43 AM | americanbankingnews.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald Sells 663 SharesAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Kevin Joseph Fitzgerald sold 663 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the sale, the executive vice president now directly owns 14,321 shares in the company, valued at $3,654,862.41. The trade was a 4.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.February 19 at 5:15 PM | marketbeat.comJeffrey V. Poulton Sells 967 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) StockAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CFO Jeffrey V. Poulton sold 967 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. The trade was a 2.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.February 19 at 5:15 PM | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet Sells 1,213 SharesAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. This represents a 1.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.February 19 at 5:15 PM | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Sells $362,246.40 in StockAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares in the company, valued at approximately $3,240,344.36. The trade was a 10.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 19 at 5:15 PM | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg Sells 1,548 SharesAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CMO Pushkal Garg sold 1,548 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at $3,017,271.63. This trade represents a 11.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.February 19 at 5:15 PM | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells $398,320.37 in StockAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CMO Pushkal Garg sold 1,561 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $398,320.37. Following the transaction, the chief marketing officer now directly owns 13,537 shares of the company's stock, valued at $3,454,236.29. This represents a 10.34 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.February 19 at 5:15 PM | marketbeat.comCanaccord Genuity Group Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock PriceCanaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a "buy" rating in a research note on Tuesday.February 19 at 8:07 AM | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Down 6.7% in JanuaryAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) was the target of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 2,940,000 shares, a drop of 6.7% from the January 15th total of 3,150,000 shares. Based on an average daily volume of 708,000 shares, the short-interest ratio is currently 4.2 days.February 19 at 7:21 AM | marketbeat.comKevin Joseph Fitzgerald Sells 663 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) StockFebruary 19 at 4:31 AM | insidertrades.comMirum Pharmaceuticals (NASDAQ:MIRM) versus Alnylam Pharmaceuticals (NASDAQ:ALNY) Head-To-Head ReviewFebruary 19 at 1:13 AM | americanbankingnews.comAlnylam price target raised to $385 from $384 at CanaccordFebruary 18 at 8:47 AM | markets.businessinsider.comRhumbline Advisers Has $42.26 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Rhumbline Advisers decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 1.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 179,578 shares of the biFebruary 18 at 3:55 AM | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2024 Earnings Call TranscriptFebruary 17, 2025 | msn.comBaillie Gifford & Co. Sells 846,741 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Baillie Gifford & Co. lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 17.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,040,259 shares of the biopharmaceutical company's stock after selling 846February 17, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest UpdateAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) saw a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 2,940,000 shares, a drop of 6.7% from the January 15th total of 3,150,000 shares. Based on an average trading volume of 708,000 shares, the days-to-cover ratio is presently 4.2 days.February 17, 2025 | marketbeat.comMorgan Stanley Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) StockFebruary 17, 2025 | americanbankingnews.comStrategic Financial Concepts LLC Invests $41.53 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Strategic Financial Concepts LLC acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 176,485 shares of the biopharmaceutical company's stock, valued at approximately $41,529,February 16, 2025 | marketbeat.comAsset Management One Co. Ltd. Trims Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Asset Management One Co. Ltd. lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 65,363 shares of the biopharmaceutical comFebruary 16, 2025 | marketbeat.comVan ECK Associates Corp Purchases 10,419 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Van ECK Associates Corp grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 18.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,818 shares of the biopharmaceutical compFebruary 16, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $300.00 at ScotiabankFebruary 16, 2025 | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)February 16, 2025 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given New $300.00 Price Target at ScotiabankScotiabank reduced their target price on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating on the stock in a research note on Friday.February 15, 2025 | marketbeat.comMorgan Stanley Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock PriceMorgan Stanley increased their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an "equal weight" rating in a research note on Friday.February 15, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday.February 15, 2025 | marketbeat.comAlnylam price target lowered to $300 from $310 at ScotiabankFebruary 14, 2025 | markets.businessinsider.comAlnylam Pharmaceuticals Full Year 2024 Earnings: EPS Misses ExpectationsFebruary 14, 2025 | finance.yahoo.comAlnylam Pharmaceuticals Inc (ALNY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...February 14, 2025 | finance.yahoo.comAlnylam Pharmaceuticals sees $1.6B to $1.725B TTR revenue in 2025 driven by AMVUTTRA expansionFebruary 14, 2025 | msn.comAlnylam Pharma (ALNY) Gets a Buy from BarclaysFebruary 14, 2025 | markets.businessinsider.comMorgan Stanley Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)February 14, 2025 | markets.businessinsider.comQ4 2024 Alnylam Pharmaceuticals Inc Earnings CallFebruary 14, 2025 | finance.yahoo.comCapital Research Global Investors Expands Stake in Alnylam Pharmaceuticals IncFebruary 13, 2025 | gurufocus.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Announces Earnings Results, Misses Estimates By $0.03 EPSAlnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03).February 13, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPSAlnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03).February 13, 2025 | marketbeat.comAlnylam Delivers a Big Q4 Earnings BeatFebruary 13, 2025 | fool.comAlnylam Pharmaceuticals Inc (ALNY) Reports Strong 2024 Financial Results and Strategic AdvancementsFebruary 13, 2025 | gurufocus.comAlnylam Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 13, 2025 | seekingalpha.comAlnylam reports Q4 EPS (6c), consensus (14c)February 13, 2025 | markets.businessinsider.comAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period ProgressFebruary 13, 2025 | finance.yahoo.comAlnylam Pharmaceuticals reports mixed Q4 results; initiates FY25 outlookFebruary 13, 2025 | seekingalpha.comSavant Capital LLC Has $2.76 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Savant Capital LLC lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 57.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,738 shares of the biopharmaceutical company's stock after purFebruary 13, 2025 | marketbeat.comAlnylam Pharmaceuticals Q4 2024 Earnings PreviewFebruary 12, 2025 | seekingalpha.comArrowhead Pharmaceuticals (ARWR) Gets a Buy from RBC CapitalFebruary 12, 2025 | markets.businessinsider.comRBC Capital maintains $300 target on Alnylam stock, optimistic on accessFebruary 11, 2025 | msn.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given Outperform Rating at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday.February 11, 2025 | marketbeat.comPliant Therapeutics (PLRX) Gets a Buy from TD CowenFebruary 10, 2025 | markets.businessinsider.comSumitomo Mitsui Trust Group Inc. Purchases 8,462 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Sumitomo Mitsui Trust Group Inc. raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 286,703 shares of theFebruary 10, 2025 | marketbeat.com Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNY Media Mentions By Week ALNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALNY News Sentiment▼0.520.60▲Average Medical News Sentiment ALNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALNY Articles This Week▼3612▲ALNY Articles Average Week Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Gilead Sciences News Vertex Pharmaceuticals News Regeneron Pharmaceuticals News Biogen News United Therapeutics News Incyte News BioMarin Pharmaceutical News Neurocrine Biosciences News Exelixis News Exact Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALNY) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
